|By PR Newswire||
|September 3, 2014 08:45 AM EDT|
ROCKVILLE, Md., Sept. 3, 2014 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it received a payment of $1 million, representing the last tranche of a $2.5 million product license and securities purchase agreement with G-treeBNT Co., Ltd, to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. G-treeBNT purchased 8,333,333 shares of common stock at $0.12 per share and retains an option until January 31, 2015 to purchase additional common stock for $825,000 at $0.15 per share. The licensing and securities purchase agreements have previously been filed as exhibits to the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2014.
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements concerning the development and potential future commercialization of RGN-137 and RGN-259, and possible future milestone payments or exercise of G-treeBNT's equity option. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can also be no assurance that any license agreement or product development program undertaken by RegeneRx or its licensees will be commercially successful. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
SOURCE RegeneRx Biopharmaceuticals, Inc.
Aug. 31, 2016 09:00 PM EDT Reads: 2,073
Aug. 31, 2016 09:00 PM EDT Reads: 336
Aug. 31, 2016 08:15 PM EDT Reads: 332
Aug. 31, 2016 07:45 PM EDT Reads: 1,965
Aug. 31, 2016 07:15 PM EDT Reads: 254
Aug. 31, 2016 07:00 PM EDT Reads: 267
Aug. 31, 2016 06:30 PM EDT Reads: 2,537
Aug. 31, 2016 06:15 PM EDT Reads: 3,629
Aug. 31, 2016 06:15 PM EDT Reads: 312
Aug. 31, 2016 06:15 PM EDT Reads: 223
Aug. 31, 2016 05:15 PM EDT Reads: 309
Aug. 31, 2016 05:00 PM EDT Reads: 886
Aug. 31, 2016 04:45 PM EDT Reads: 3,855
Aug. 31, 2016 04:15 PM EDT Reads: 990
Aug. 31, 2016 04:00 PM EDT Reads: 1,152